Ready For Risk Sharing? Performance-Based Agreements as a Catalyst of Innovative Pharmacotherapy

• Autorzy: Weronika Wojturska
• Języki publikacji: EN

Abstrakty

EN

Since health authorities and pharmaceutical companies are risk-averse in the reimbursement process, risk-sharing agreements (RSAs) can be seen as a happy medium for ensuring that the inherent financial and clinical risks of implementing a new innovative treatment are minimized. Although a properly applied RSA lies in the interest of patients, payers and manufacturers, the initial analysis shows that implementation of performance-based RSAs (PBRSAs), tied to measurable health outcomes, faces numerous obstacles in Poland. The article seeks to propose solutions, taking into account the characteristics of PBRSAs in Italy and the United Kingdom. The analysis is in line with the current trend of gradual remodelling of the Polish system towards value-based healthcare. The methods employed include a broad conceptual and exploratory analysis of Polish and foreign literature and legal acts, data acquired from national health data repositories, materials published by pharmaceutical consortia, financial institutions and public authorities engaged in managing the medicine market in Europe. (original abstract)

Słowa kluczowe

EN

Risk; Financial risk; Reimbursement of medicines; Pharmaceutical market

PL

Ryzyko; Ryzyko finansowe; Refundacja leków; Rynek farmaceutyczny

• Czasopismo: Polish Journal of Political Science
• Rocznik: 2023
• Tom: 9
• Numer: nr 3
• Strony: 30--49

Twórcy

autor

Weronika Wojturska

• University of Warsaw, Poland

Bibliografia

• Ustawa z dnia 12 maja 2011 r. o refundacji leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych, Dz. U. 2011 Nr 122 poz. 696 z późn. zm., [Act of 12 May 2011 on the reimbursement of medicines, foodstuffs for special nutritional purposes and medical devices, Journal of Laws 2011, No. 122, item 696 as amended].
• Adamski J., Godman B., Ofierska-Sujkowska G., Osińska B., Herholz H., Wendykowska K., Laius O., Jan S., Sermet C., Zara C., Kalaba M., Gustafsson R., Garuolienè K., Haycox A., Garattini S., Gustafsson L.L., Correspondence Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers, "BMC Health Services Research", 2010, Vol. 10, pp. 1-16, DOI: 10.1186/1472-6963-10-153.
• Aggarwal R., Risk-sharing Agreements: Country Experiences and Challenges, 2014, pp. 1-8, https://www.insead.edu/sites/default/files/assets/dept/centres/hmi/docs/rsa-experiencesandchallenges-insead-hmi.pdf, (access 01.08.2023).
• Barros P.P., Pharmaceutical policies in European countries, "AdvHealth Econ Health Serv Res.", 2010, Vol. 22, pp. 3-27, DOI: 10.1108/s0731-2199(2010)0000022004.
• Boggild M., Palace J., Barton P., Ben-Shlomo Y., Bregenzer T., Dobson Ch., Gray R., Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator, "BMJ", 2009, Vol. 339, pp. 1-9, DOI: 10.1136/bmj.b4677.
• Breckenridge A., Walley T., Risk sharing and payment by results, "Clin Pharmacol Ther.", 2008, Vol. 83 (5), pp. 666-667, DOI: 10.1038/clpt.2008.15.
• Buch C., Schildmann J., Zerth J., Risk-sharing schemes to finance expensive pharmaceuticals: Interdisciplinary analyses, in: Defining the Value of Medical Interventions: Normative and Empirical Challenges, eds. J. Schildmann, C. Buch, J. Zerth, W. Kohlhammer GmbH 2021, https://www.ncbi.nlm.nih.gov/books/NBK585090/

Identyfikatory

DOI

10.58183/pjps.03042023